Showing posts with label honey for wound healing. Show all posts
Showing posts with label honey for wound healing. Show all posts

Friday, December 12, 2014

Honey for Cesarean Wound Healing?


We've discussed honey for wound healing before, and specifically for cesarean wound healing.

We talked about the mechanics of how honey (medical grade honey, not supermarket honey) might help healing and what studies there were on the topic.

As one review notes:
Honey has anti-oxidant, anti-bacterial and anti-inflammatory properties. It can be used as a wound dressing to promote rapid and improved healing. These effects are due to honey's anti-bacterial action, secondary to its high acidity, osmotic effect, anti-oxidant content and hydrogen peroxide content. The use of honey leads to improved wound healing in acute cases, pain relief in burn patients and decreased inflammatory response in such patients...There is biological plausibility.
Mixed Results

While honey has "biological plausibility" as a healing agent, results from use of medical grade honey have been encouraging in some situations and discouraging in others. Results were not very good for venous ulcers, for example, but on some wounds there are better results.

A recent Cochrane review found decidedly mixed results, depending on what type of wound was being studied, and cautioned against its routine use until more data is available. So it's hard to know just how useful medical grade honey really is, and how much is just hype.

The problem is that much of the honey-based research is sponsored by the companies that make medical-grade honey, so the results are at high risk for bias.

Bottom line.....better data is needed. But given the positive results in some studies and its relatively low cost, why haven't there been more well-controlled studies done by independent groups by now?

Medical-Grade Honey for Cesarean Healing

Sadly, there's not a lot of data on using honey for cesarean wound healing. There are a couple of older studies done in third-world countries, but they had small data sets and uncontrolled conditions. As a result, using medical honey on a cesarean wound has not been been embraced in Western countries.

Now there's a new study on the use of honey for abdominal wound healing after cesarean. The data set is still very small and still from a third-world country, but at least the study design is randomized and blinded. The results from this study were encouraging.

This doesn't prove honey is a healing agent of choice for cesarean wounds, but it certainly points to the need for bigger and better studies to further examine the question. 

I would particularly like to see medical-grade honey investigated in the treatment of cesarean wound infections of "obese" women (who are substantially more at-risk for wound infection than other women).

About 15-30% of high-BMI women will experience a wound infection after a cesarean, and sometimes these infections last for months. Wound infections like this can be devastating to a new mother, can interfere with breastfeeding, and are costly to treat.

Many cesarean wound infections in obese women can likely be lowered by using more appropriate dosages of antibiotics, but medical grade honey might give another weapon in the arsenal against infections in this group of women.

Of course, the best treatment is prevention of the cesareans in the first place whenever possible, which is why the 40-80% cesarean rate in "morbidly" and "super obese" women is so completely unacceptable.

But sometimes cesareans truly are necessary. When cesareans do occur in this group of women, more tools are needed to help prevent or treat the wound infections that will result in some of them.

Medical-grade honey might be yet another tool in the toolbox for this situation. And it's past time for Western medicine to investigate this possibility more thoroughly.


Reference

Oman Med J. 2014 Jul;29(4):255-9. doi: 10.5001/omj.2014.68. The effect of honey gel on abdominal wound healing in cesarean section: a triple blind randomized clinical trial. Nikpour M1, Shirvani MA2, Azadbakht M3, Zanjani R4, Mousavi E5. PMID: 25170405
OBJECTIVE: To assess whether honey can accelerate the wound healing in women undergoing cesarean section. METHODS: This was a triple blinded randomized prospective clinical trial. Women with cesarean section were randomly designated as drug (37 cases) and placebo (38 cases) groups. The drug group received local honey gel 25% while the placebo group received similar free-honey gel on abdominal cesarean incision twice a day for 14 days. REEDA scale (Redness, Edema, Ecchymosis, Discharge and Approximation of wound edges) was used to assess wound healing. RESULTS: The mean REEDA was 2.27 ± 2.46 and 3.91 ± 2.74 (p=0.008) on the 7(th) day and 0.47 ± 0.84 and 1.59± 1.95 (p=0.002) on the 14(th) day for the drug and placebo groups, respectively. Redness, edema and hematoma in the drug group were significantly lower on the 7(th) and 14(th) days. CONCLUSION: Honey was effective in healing the cesarean section incision. Using topical honey is suggested as a natural product with rare side effects in order to reduce the complications of cesarean wounds.

Thursday, August 16, 2012

Lowering the Risk for Surgical Site Infections in Fat Folk

Image from Chopra 2010 study, link below
We've discussed prevention of surgical site infections before, often in the context of cesareans, but most recently in the context of Emergency Room visits.

Regardless of type of operation, however, accumulating evidence suggests that antibiotic regimens for "obese" people need to be adjusted.

We in the Size Acceptance Movement have been saying for years that people of size often benefit from larger or weight-based dosing for certain types of antibiotics, longer courses of antibiotics in some cases, and IV antibiotics instead of oral antibiotics for serious infections.

This was based on the anecdotal experiences of many people of size over the years, and as such, was summarily dismissed by many in the medical community.

Here is research that confirms the importance of longer courses of antibiotics and weight-based dosing, and which also suggests that more frequent dosing, administration of antibiotics by IV, and perhaps topical infusion of antibiotics into the wound  itself before closing (instead of just systemically in the IV) seem to improve outcomes.

Of course, different types of antibiotics work differently in the system. This means that some types of antibiotics need different dosing for obese people and some don't.  That's important to remember ─ the need for weight-based dosing is not universal for all drugs.  And to be fair to doctors, research has been slow to differentiate these and to provide easy-to-use guidance to doctors in their prescriptions.

Yet there is some research that addresses this issue now, but as we saw recently in the Emergency Room study, getting doctors to follow this research is difficult. In that study, simple guidelines for dosing for high-BMI patients in the E.R. were readily available, but even so, less than 5% of morbidly obese patients received the proper initial dosage of common antibiotics. And that was at a medical center that specialized in treating obese patients!

Furthermore, another study has shown that hospital pharmacists often do not catch/correct underdosing errors in high-BMI patients.  In that study, less than 1/3 of obese patients received an adequate initial dose of vancomycin, only 1% received the optimum recommended dose, and only about 3% of these underdosing cases were caught and corrected by hospital pharmacists.

Far too often, people of size are still being treated with standard antibiotic dosages instead of dosages tailored to their weight, or antibiotics given too infrequently, orally, or for an insufficient length of time.

When will doctors listen to people of size and learn from our experiences?  Heck, when will they learn from their own research?

What is the barrier to adopting these new regimens?  Why aren't they being utilized far more often?  Why aren't hospital pharmacists or medical supervisors catching more inadequate dosing and raising red flags about it?

It's frustrating that this topic is only now being researched and that many hospitals ─ even those that specialize in treating obese patients ─ have been slow to utilize the new dosing guidelines that do exist.

As people of size, we need to be our own best advocates, both before surgery and when surgical site infections occur, so don't be afraid to bring up this concern with your surgeon, or to ask for a consult with an infectious specialist.  Even with a specialist, you may have to be ready to assertively argue your case, but they are more likely to be responsive to advocacy if you can cite research like the studies below.

Providers, please press hard for more research on the most optimal antibiotic dose and regimens, and press vigorously for more caregiver education about and usage of these regimens.  If there is any question about optimal dosage, please take the time to research the issue, and don't be afraid to explore using a different timing or delivery system.  It could literally be the difference between life and death for some people of size.

Infections can be a significant problem in high-BMI patients. Part of this is because of physiological differences like decreased vascular perfusion in fat tissue, and thus decreased oxygenation.  But an under-recognized part of it is because clinicians are using the wrong dosages and treatment regimens for fat folk.

The most efficient approach to improving outcome in obese patients is still to prevent infection in the first place by using the most effective antibiotic dose and treatment protocols available for our unique needs.


References

Am J Obstet Gynecol. 2010 Mar;202(3):306.e1-9. Extended antibiotic prophylaxis for prevention of surgical-site infections in morbidly obese women who undergo combined hysterectomy and medically indicated panniculectomy: a cohort study. El-Nashar SA, et al.   PMID: 20207249
OBJECTIVE: The purpose of this study was to compare surgical-site infection rates in obese women who had extended prophylactic antibiotic (EPA) vs standard prophylactic antibiotic.
STUDY DESIGN: An electronic records-linkage system identified 145 obese women (body mass index, >30 kg/m(2)) who underwent combined hysterectomy and panniculectomy from January 1, 2005, through December 31, 2008. The EPA cohort received standard antibiotics (cefazolin, 2 g) and continued oral antibiotic (ciprofloxacin) until removal of drains. Regression models were used to adjust for known confounders. RESULTS:The mean age was 56.0 + or - 12.1 years, and mean body mass index was 42.6 + or - 8.4 kg/m(2) (range, 30-86.4 kg/m(2)). The EPA cohort experienced fewer surgical-site infections (6 [5.9%] vs 12 [27.9%]; P less than .001; adjusted odds ratio, 0.16; 95% confidence interval, 0.04-0.51; P less than .001), had lower probability of incision and drainage (3 [2.9%] vs 5 [11.6%]; P = .05), and required fewer infection-related admissions (5 [4.9%] vs 6 [13.9%]; P = .08). CONCLUSION: Extended antibiotic prophylaxis can reduce surgical-site infections in obese women after combined hysterectomy and panniculectomy.
Surg Infect (Larchmt). 2009 Feb;10(1):53-7. Prevention of surgical site infections by an infusion of topical antibiotics in morbidly obese patients. Alexander JW, Rahn R, Goodman HR.  PMID: 19245364 
BACKGROUND: The reported incidence of surgical site infection after abdominal surgery in morbidly obese patients is high (about 15% in most studies), and this is associated with considerable disability and an increased economic burden. Topical antibiotics may reduce the incidence of serious infections. METHODS: Standard techniques for the prevention of surgical site infections were used along with the introduction of kanamycin into the subcutaneous space of morbidly obese patients at the time of closure and allowing it to dwell for 2 h. Eight hundred thirty-seven evaluable patients were followed for the development of site complications for at least six weeks postoperatively. RESULTS: One of the 65 patients with a revisional procedure had a primary deep incisional surgical site infection, as did one of the 772 patients with a primary operation. Secondary deep incisional surgical site infections occurred in four patients, two after spontaneous evacuation of a seroma, one from excessive superficial contamination, and one following separation of a nonhealing surgical site. Additionally, 21 patients had minor surgical site complications including incisional separation and stitch-related infections, which required no significant expenditure of resources. CONCLUSIONS: Prolonged contact (2 h) of topical kanamycin solution with the surgical site greatly reduces the incidence of primary infections in the deep subcutaneous space of laparotomy sites in morbidly obese patients.
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):317-28. Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens. Chopra T, et al.   PMID: 20545596    Full free text available here.
Kmom Summary: This paper reviews the surgical site infections (SSIs) that occur post bariatric surgery, and how to prevent SSIs. "This paper sets out to define different types of SSIs that occur following bariatric surgery and to discuss existing literature on the critical aspects of SSI prevention and the appropriate use of surgical antimicrobial prophylaxis for bariatric surgery."   
Important quote: "Most antimicrobial agents do not achieve optimal serum levels when administered orally. Although certain oral antimicrobials have comparable bioavailability with their intravenous formulation, the time to achieve maximum serum concentration is slower due to the need for absorption through the gastrointestinal tract. Intravenous antimicrobial prophylaxis is the most extensively studied route and remains the preferred route of administration."
Obes Surg. 2012 Mar;22(3):465-71. Cefepime dosing in the morbidly obese patient population. Rich BS, et al.  PMID: 22249886
Proper dosing of specific antibiotics in morbidly obese patients has been studied inadequately. However, these data are beneficial as this patient population is at an increased risk to develop postoperative infections. Cefepime is an antibiotic used for the treatment of both gram-positive and especially gram-negative infections; administration of the appropriate dose in the morbidly obese population is crucial. We therefore examined the pharmacokinetics of cefepime in patients with body mass index >40 kg/m(2). Ten morbidly obese patients, with a mean [±SD] estimated glomerular filtration rate of 108.4 ± 34.6 mL/min, undergoing elective weight loss surgical procedures were administered cefepime in addition to standard prophylactic cefazolin and studied. Serial serum cefepime concentrations were analyzed after dosing using a validated high performance liquid chromatography method. Pharmacokinetics and duration above the minimum inhibitory concentration (MIC) were determined using a protein binding value of 15% and a MIC threshold of 8 μg/mL. Mean free cefepime concentrations for t = 30, 120, and 360 min were 69.6, 31.6, and 9.2 μg/mL, respectively. The dosing interval was calculated to maintain the free concentration above the MIC (fT > MIC) for 60% of the interval. This was determined to be 10.12 h, including time for infusion. There was no toxicity. Based on this analysis, an increased dose of 2 g every 8 h is necessary to maintain an adequate fT > MIC throughout the dosing interval. Further studies are necessary to determine the efficacy of this regimen in the settings of active infections and critical illness.
Pharmacotherapy. 2007 Aug;27(8):1081-91.  Antimicrobial dosing considerations in obese adult patients. Pai MP, Bearden DT.    PMID: 17655508
As obesity continues to increase in prevalence throughout the world, it becomes important to explore the effects that obesity has on antimicrobial disposition. Physiologic changes in obesity can alter both the volume of distribution and clearance of many commonly used antimicrobials. These changes often present challenges such as estimation of creatinine clearance to predict drug clearance.

Although these physiologic changes are increasingly being characterized, few studies assessing alterations in tissue drug distribution and the effects of obesity on antimicrobial pharmacokinetics have been published. The available data are most plentiful for antibiotics that historically have included clinical therapeutic drug monitoring.

These data suggest that dosing of vancomycin and aminoglycosides be based on total body weight and adjusted body weight, respectively. Obese patients may require larger doses of beta-lactams to achieve similar concentrations as those of patients who are not obese. Fluoroquinolone pharmacokinetics are variably altered by obesity, which prevents a uniform approach. Data on the pharmacokinetics of drugs that have activity against gram-positive organisms-quinupristin-dalfopristin,linezolid, and daptomycin-reveal that they are altered in the presence of obesity, but more data are needed to solidify dosing recommendations. Limited data are available on nonantibacterials. 
An understanding of the physiologic changes in obesity and the available literature on specific antibiotics is valuable in providing a framework for rational selection of dosages in this increasingly common population of obese patients.
Am J Med. 2008 Jun;121(6):515-8.  Multicenter evaluation of vancomycin dosing: emphasis on obesity. Hall RG 2nd, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, Busti AJ, Vu SL, Bedimo R.    PMID: 18501233 Full text available here.
BACKGROUND: There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight. METHODS: This study was conducted at 2 tertiary care medical centers that did not have pharmacy-guided vancomycin dosing programs or other institutional vancomycin dosing policies or protocols. Patients who received vancomycin between July 1, 2003, and June 30, 2006, were stratified by body mass index and randomly selected from the computer-generated queries. Patients greater or equal to 18 years of age with a creatinine clearance of at least 60 mL/min who received vancomycin for at least 36 hours were included. RESULTS: Data were collected on a random sampling of 421 patients, stratified by body mass index, who met the inclusion criteria. Most patients in each body mass index category received a fixed dose of vancomycin 2 g daily divided into 2 doses (underweight 82%, normal weight 90%, overweight 86%, and obese 91%).  
Adequate initial dosing (greater than or=10 mg/kg/dose) was achieved for 100% of underweight, 99% of normal weight, 93.9% of overweight, and 27.7% of obese patients (P less than .0001).

Ninety-seven percent of underweight, 46% of normal weight, 1% of overweight, and 0.6% of obese patients received greater than or =15 mg/kg/dose recommended by several Infectious Diseases Society of America guidelines.

Pharmacists also failed to correct inadequate dosing because only 3.3% of patients receiving less than 10 mg/kg/dose had their regimen changed in the first 24 hours of therapy.

CONCLUSION: In this multicenter pilot study, obese patients routinely received inadequate empiric vancomycin using a lenient assessment of dosing. Greater efforts should be undertaken to ensure patients receive weight-based dosing because inadequate dosing can lead to subtherapeutic concentrations and potentially worse clinical outcomes.
Eur J Clin Pharmacol. 1998 Oct;54(8):621-5. Vancomycin dosing in morbidly obese patients. Bauer LA, Black DJ, Lill JS.   PMID: 9860149 
OBJECTIVES AND METHODS: Vancomycin hydrochloride dosing requirements in morbidly obese patients with normal renal function were computed to determine the dose of vancomycin necessary to achieve target steady-state peak and trough concentrations and compared with a normal weight population.  RESULTS: Morbidly obese patients [total body weight (TBW) 165 kg, ideal body weight (IBW) 63 kg] required 31.2 mg x kg(-1) x d(-1) TBW or 81.9 mg x kg(-1) x d(-1) IBW to achieve the target concentrations. Normal weight patients (TBW 68.6 kg) required 27.8 mg x kg(-1) x d(-1) to achieve the same concentrations. Because of altered kinetic parameters in the morbidly obese patients (obese: t1/2 = 3.3 h, V = 52 L, CL = 197 ml x min(-1); normal: t1/2=7.2 h, V=46 L, CL=77 ml x min(-1), 20 of 24 patients required q8h dosing (1938 mg q8h) compared with q12h dosing (954 mg q12h) in all normal weight patients in order to avoid trough concentrations that were too low for prolonged periods. There was a good correlation between TBW and CL, but only fair correlation between TBW and V. CONCLUSION: Doses required to achieve desired vancomycin concentrations are similar in morbidly obese and normal weight patients when TBW is used as a dosing weight for the obese (approximately 30 mg x kg(-1) x d(-1)). Shorter dosage intervals may be needed when dosing morbidly obese patients so that steady-state trough concentrations remain above 5 microg x ml(-1) in this population. Because of the large amount of variation in required doses, vancomycin serum concentrations should be obtained in morbidly obese patients to ensure that adequate doses are being administered. Dosage requirements for morbidly obese patients with renal dysfunction require further study.
Surgery. 2004 Oct;136(4):738-47. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Edmiston CE, et al.    PMID: 15467657
BACKGROUND: Perioperative surgical antibiotic prophylaxis requires that therapeutically effective drug concentrations be present in the tissues. METHODS: Patients undergoing Roux-en-Y gastric bypass for morbid obesity were given 2 g cefazolin preoperatively, followed by a second dose at 3 hours. Thirty-eight patients were each assigned to 1 of 3 body mass index (BMI) groups: (A) BMI=40-49 (N = 17); (B) BMI=50-59 (N=11); (C) BMI > or= 60 (N=10). Multiple timed serum (baseline; incision, 15, 30, 60 minutes; prior to second prophylactic dose; and closure) and tissue (skin, subcutaneous fat, and omentum) specimens were collected and cefazolin concentration analyzed by microbiological assay. RESULTS: No significant difference was observed in intraoperative fluid replacement or blood loss among BMI groups. Serum antimicrobial concentrations exceeded resistance breakpoint (32 microg/mL) in 73%, 68%, and 52% of BMI groups A, B, and C, respectively. No significant difference in cefazolin concentration was observed in mean incisional skin and closure tissue specimens in groups A, B, and C. A significant decrease in cefazolin concentration was noted in closure adipose (p=.04), initial (p=.03) and closure omentum (p=.05) tissues in groups B and C compared with A. Over 90% of serum samples exhibited therapeutic concentrations covering 53.8% of gram-positive and 78.6% of gram-negative surgical pathogens. However, therapeutic tissue levels were achieved in only 48.1%, 28.6%, and 10.2% of groups A, B, and C, respectively. CONCLUSIONS: Pharmacokinetic analysis suggests that present dosing strategies may fail to provide adequate perioperative prophylaxis in gastric bypass patients.
Am J Emerg Med. 2011 Dec 12. Underdosing of common antibiotics for obese patients in the ED. Roe JL, Fuentes JM, Mullins ME.  PMID: 22169576
BACKGROUND: Obesity is a growing problem in the United States. Obesity alters the pharmacokinetic profiles of various drugs. Although there are guidelines for dose adjustments for many of the antibiotics commonly used in the emergency department (ED), they are seldom used. METHODS: This is an institutional review board-approved retrospective study at an American Society of Metabolic and Bariatric Surgery Center of Excellence and a level I trauma center with annual ED volumes of more than 80 000 visits. Data were retrospectively collected from ED pharmacy records during a 3-month period in 2008. Any first dose of cefepime, cefazolin, or ciprofloxacin administered in our ED to a patient recorded as both more than 100 kg and with a body mass index greater than 40 kg/m(2) was compared with our hospital guidelines and found to either adhere or not adhere to those guidelines. RESULTS: There were 1910 orders found to meet the study criteria: 775 orders for cefepime, 625 orders for cefazolin, and 510 orders for ciprofloxacin. Adherence rates for first dose of cefepime, cefazolin, and ciprofloxacin administered, respectively, were 8.0%, 3.0%, and 1.2%. CONCLUSION: Emergency physicians frequently underdose cefepime, cefazolin, and ciprofloxacin in obese patients. Underdosing antimicrobials presents risk of treatment failure and may promote antimicrobial resistance. Education is necessary to improve early antibiotic administration to obese patients.

Sunday, November 6, 2011

Honey for Wound Healing?

One of the most interesting bits of folk medicine to enjoy a resurgence has been the use of honey for wound healing.

Honey was often used by the ancient Egyptians and Greeks for wound healing.  It was used at times in the modern era as well ─ until the mid 20th century.  After antibiotics were invented, it went out of common use in Western countries, but was still used to some degree in third-world countries as a folk remedy.

In the last 20 years or so, honey has experienced a resurgence of use, and a number of studies have investigated its utility in wound care.  However, at this time, research on honey for wound-care is lagging inside the United States, despite the fact that medical honey dressings were approved by the FDA a few years ago.

It's time that honey for wound care be investigated more thoroughly, both here in the United States and abroad, in various low- and high-resource settings.  We need much more data on when and how it is best utilized because it looks like a promising weapon in the fight against antibiotic-resistant bacteria.

How Does Honey Help Healing?

One review of the topic discussed why honey has come back into use:
Dressing wounds with honey, a standard practice in past times, went out of fashion when antibiotics came into use. Because antibiotic-resistant bacteria have become a widespread clinical problem, a renaissance in honey use has occurred. Laboratory studies and clinical trials have shown that honey is an effective broad-spectrum antibacterial agent that has no adverse effects on wound tissues. As well as having an antibacterial action, honey also provides rapid autolytic debridement, deodorizes wounds, and stimulates the growth of wound tissues to hasten healing and start the healing process in dormant wounds. Its anti-inflammatory activity rapidly reduces pain, edema, and exudate and minimizes hypertrophic scarring. It also provides a moist healing environment for wound tissues with no risk of maceration of surrounding skin and completely prevents adherence of dressings to the wound bed so no pain or tissue damage is associated with dressing changes. Using appropriate dressing practice overcomes potential messiness and handling problems.
Honey works on several fronts.  First, the sugar in it draws out moisture from bacteria in the wound through osmotic action, and this plus the acidity of honey inhibits the growth of bacteria.  Second, it draws more lymph fluid into the wound, which speeds healing. Third, the honey forms a barrier to protect the wound from outside infections, and provides a moist environment that helps promote tissue regrowth and minimize scarring. Fourth, it has an enzyme which produces hydrogen peroxide in a dilute form, which helps disinfect the area without damaging the skin the way the commercially-available hydrogen peroxide does.  Finally, it keeps bandages from sticking to wounds as they heal, making dressing changes easier and less damaging to skin as it works to heal.

It's likely that there are other ways in which honey helps healing, but these seem to be the main modes of healing that we have figured out so far.

The biggest advantage of honey is that it does not promote antibiotic resistance, and that it's often effective against antibiotic-resistant "superbugs" like MRSA.  Honey's most important use currently may be in treating wounds infected with antibiotic-resistant bugs.  However, it may be that honey could have an important preventative role before antibiotic-resistant infections ever take hold.  Only further research will tell.

Since bees make honey from varying plant sources, different kinds of honey can have different levels of antibacterial effects.  In other words, some honeys may be more effective than others.

Research has mostly been done on Manuka Honey (marketed as Medihoney) from New Zealand, which supposedly has greatly increased antibacterial properties compared to many other honeys.  However, this company's aggressive marketing has led some to question whether its claim of superiority is more marketing than substance. Tualang honey from Malaysia is also being researched, as well as RS honey (Revamil honey) from The Netherlands; many other honeys from other countries are sure to follow.  New Zealand, Germany, and the Netherlands are the countries currently leading the research surge on medical-grade honey.

It's important to note that honey used in research is different from ordinary honey you might get from the supermarket.  It's not clear whether research honey is more effective than supermarket honey, but it seems likely.  In addition, impurities within honey (and botulism spores) lead some companies to irradiate their honey before marketing it. Therefore, at this time, most authorities do not promote the use of ordinary over-the-counter honey for wound healing.  Medical-grade honey is what has been studied.

A Brief Summary of the Research

Research suggests that medical-grade honey is quite effective for improving healing in burn patients.  A 2009 meta-analysis of studies found that patients treated with honey had better healing.  The authors concluded:
Available evidence indicates markedly greater efficacy of honey compared with alternative dressing treatments for superficial or partial thickness burns, although the limitations of the studies included in the meta-analysis restrict the clinical application of these findings. Further studies are urgently required to determine the role of honey in the management of superficial or partial thickness burns.
However, the use of honey in patients with leg ulcers has been less convincing.  Jull 2008 did a randomized clinical trial and found that treatment with honey did not improve healing. On the other hand, Gethin and Cowman (2009) found that honey did have some beneficial effect on desloughing ulcers and minimizing infection.

One problem is that many medical honey trials have been less than rigorous.  They often come from only one or two main centers, and frequently are run or funded by companies who produce medical-grade honey. Furthermore, difficulties with study design (use of medical-grade honey vs. ordinary honey, inconsistent antibacterial properties of honey between batches of the same honey, use of honey only after very serious infections are already present) have also limited the clinical application of the findings of existing studies.

The 2008 Cochrane review of honey in wound care concludes:
Honey may improve healing times in mild to moderate superficial and partial thickness burns compared with some conventional dressings. Honey dressings as an adjuvant to compression do not significantly increase leg ulcer healing at 12 weeks. There is insufficient evidence to guide clinical practice in other areas.
In other words, although many results are encouraging, not all are, and many studies weren't well-designed.  Larger, more rigorous and more independent trials are needed to determine how and when honey is most effective.

Honey in Childbearing Women

What about the use of honey for healing in childbearing women?

One 1992 study found that honey helped heal infected cesarean wounds within 2 weeks and avoided the need for re-suturing the wound under general anesthesia.

A 1999 study found that in infections after either a cesarean or a hysterectomy, women treated with honey did better than women treated with traditional topical antiseptics (both groups received systemic antibiotics).  The healing time in the honey-treated patients was cut in half, women needed far less time on antibiotics, 84% of the honey-treated group experienced complete healing (vs. 50% in the topical antiseptic group), and none of the honey-treated group needed re-suturing (vs. one-fourth of the topical antiseptic group).

The problem with the research on honey for post-cesarean healing is that the studies are extremely small, not very recent, and were done only in third-world countries with more outdated wound-care practices.  However, the two studies that exist are encouraging and indicate that the possibility should definitely be tested more rigorously.

Some midwives also use honey for minor perineal tears after birth.  Demetria Clark, herbalist, quoting from various sources, explains why honey can be helpful:
Raw honey is a great remedy for first-degree [perineal] tears. Honey's thick consistency forms a barrier defending the wound from outside infections. The moistness allows skin cells to grow without creating a scar, even if a scab has already formed. Meanwhile, the sugars extract dirt and moisture from the wound, which helps prevent bacteria from growing, while the acidity of honey also slows or prevents the growth of many bacteria. An enzyme that bees add to honey reacts with the wound's fluids and breaks down into hydrogen peroxide, a disinfectant. Honey also acts as an anti-inflammatory and pain killer and prevents bandages from sticking to wounds. Laboratory studies have shown that honey has significant antibacterial qualities. Significant clinical observations have demonstrated the effectiveness of honey as a wound healing agent. Glucose converted into hyaluronic acid at the wound surface forms an extracellular matrix that encourages wound healing. Honey is also considered antimicrobial. 
From Volume 11, Issue 1, January 7, 2009 edition of Midwifery Today enews
Excerpted from "Herbs for Postpartum Perineum Care: Part I," The Birthkit, Issue 46
http://www.midwiferytoday.com/products/bk46.htm 
Obesity, Diabetes, and Medical Grade Honey

In particular, it would be helpful to know if medical-grade honey could help lessen the incidence of wound infection in women of size, who have a higher rate of infection after cesareans or other operations.  Or if it could lessen infection in diabetics, who are also quite prone to surgical site infections and poorly-healing skin ulcers.

Yet I have seen some experts recommend against using honey in these groups, on the assumption that it would raise the blood sugar of the patient, and thereby inhibit healing. However, this seems to be just that, an assumption rather than a proven fact, and needs to be tested before such groups are routinely excluded from such potentially promising treatment.

Some authors have also speculated that the high rates of methylglyoxal (MG) in Manuka honey (MediHoney) will impair healing in diabetic ulcers.  But again, this theory has not yet been tested.

At this point, I have not seen definitive studies done to test the hypothesis that honey is unsuited for use in either of these groups.  Diabetics were routinely excluded from many of the venous leg ulcer studies that were done, and I don't know of any studies done specifically on "obese" people.

However, we do have small studies and case reports of MediHoney being used successfully on diabetics, indigent diabetics with chronic wounds, and in people of size─with promising results─but we need systematic study before we jump to conclusions.

It is unfair to exclude fat people and diabetics from the potentially healing properties of medical-grade honey based on unproven assumptions.

Instead of excluding these populations, studies specifically examining outcomes in these populations should be done, utilizing various brands of medical-grade honey and wound-care protocols.  Only then will we know whether exclusions from topical honey dressings is justified or not.

Conclusion

The FDA approved the use of honey for wound dressings in 2007, but U.S.-based research on honey dressings has been slow to catch on, and has been centered mostly on burns and leg ulcers.

Perhaps it's time that its use in other types of wounds, in childbearing women, in diabetics, and in people of size is investigated more thoroughly.

Clearly, we need more information and better studies before we can know just how helpful (or not) medical-grade honey might be.

But given its cost-effectiveness, its potential for lowering antibiotic resistance issues, and the possibility of improving outcome in those with difficult-to-heal wounds, it's a subject that deserves larger and better trials.

*Caution: Honey should not be used for very young children (especially newborns) because it can harbor botulism spores.  Therefore many healthcare providers feel medical honey should not be used on anything that might come in contact with newborns either internally or externally (i.e. not for sore nipples or for cord healing after birth).  


Honey dressings are well-tolerated by most people who use them, but occasionally a few people report a stinging sensation with their use at first.  Those who are allergic to bee stings might also need to use extra caution with medical honey.


References

Honey for Wound Healing 
Am J Clin Dermatol. 2011 Jun 1;12(3):181-90.  Honey and wound healing: an overview. Lee DS, Sinno S, Khachemoune A.  PMID: 21469763
Honey has been used to treat wounds throughout the ages. This practice was rooted primarily in tradition and folklore until the late 19th century, when investigators began to characterize its biologic and clinical effects. This overview explores both historic and current insights into honey in its role in wound care. We describe the proposed antimicrobial, immunomodulatory, and physiologic mechanisms of action, and review the clinical evidence of the efficacy of honey in a variety of acute and chronic wound types. We also address additional considerations of safety, quality, and the cost effectiveness of medical-grade honeys. In summary, there is biologic evidence to support the use of honey in modern wound care, and the clinical evidence to date also suggests a benefit. However, further large, well designed, clinical trials are needed to confirm its therapeutic effects.
Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005083. Honey as a topical treatment for wounds. Jull AB, Rodgers A, Walker N.  PMID: 18843679
19 trials (n=2554) were identified that met the inclusion criteria. In acute wounds, three trials evaluated the effect of honey in acute lacerations, abrasions or minor surgical wounds and nine trials evaluated the effect the honey in burns. In chronic wounds two trials evaluated the effect of honey in venous leg ulcers and one trial in pressure ulcers, infected post-operative wounds, and Fournier's gangrene respectively. Two trials recruited people with mixed groups of chronic or acute wounds. The poor quality of most of the trial reports means the results should be interpreted with caution, except in venous leg ulcers. In acute wounds, honey may reduce time to healing compared with some conventional dressings in partial thickness burns (WMD -4.68 days, 95% CI -4.28 to -5.09 days). All the included burns trials have originated from a single centre, which may have impact on replicability. In chronic wounds, honey in addition to compression bandaging does not significantly increase healing in venous leg ulcers (RR 1.15, 95%  CI 0.96 to 1.38). There is insufficient evidence to determine the effect of honey compared with other treatments for burns or in other acute or chronic wound types. AUTHORS' CONCLUSIONS: Honey may improve healing times in mild to moderate superficial and partial thickness burns compared with some conventional dressings. Honey dressings as an adjuvant to compression do not significantly increase leg ulcer healing at 12 weeks. There is insufficient evidence to guide clinical practice in other areas.
Adv Skin Wound Care. 2011 Jan;24(1):40-4. Use of honey in wound care: an update. Song JJ, Salcido R.  PMID: 21150765
The therapeutic use of honey in wound care has been used since ancient times. Honey has been shown to have antibacterial properties in vitro and animal studies have demonstrated accelerated wound healing with the use of honey. In human trials, there is currently not enough strong evidence to fully support the use of honey in wound care; however, use in minor burns and prevention of radiation mucositis appear to be 2 areas where honey shows therapeutic promise.
Br J Surg. 2008 Feb;95(2):175-82. Randomized clinical trial of honey-impregnated dressings for venous leg ulcers. Jull A, et al; Honey as Adjuvant Leg Ulcer Therapy trial collaborators.  PMID: 18161896
This community-based open-label randomized trial allocated people with a venous ulcer to calcium alginate dressings impregnated with manuka honey or usual care. All participants received compression bandaging. The primary outcome was the proportion of ulcers healed after 12 weeks. Secondary outcomes were: time to healing, change in ulcer area, incidence of infection, costs per healed ulcer, adverse events and quality of life. Analysis was by intention to treat. RESULTS: Of 368 participants, 187 were randomized to honey and 181 to usual care. At 12 weeks, 104 ulcers (55.6 per cent) in the honey-treated group and 90 (49.7 per cent) in the usual care group had healed (absolute increase 5.9 (95 per cent confidence interval (c.i.) -4.3 to 15.7) per cent; P = 0.258). Treatment with honey was probably more expensive and associated with more adverse events (relative risk 1.3 (95 per cent c.i. 1.1 to 1.6); P = 0.013). There were no significant differences between the groups for other outcomes.CONCLUSION: Honey-impregnated dressings did not significantly improve venous ulcer healing at 12 weeks compared with usual care. 
J Clin Nurs. 2009 Feb;18(3):466-74. Epub 2008 Aug 23. Manuka honey vs. hydrogel--a prospective, open label, multicentre, randomised controlled trial to compare desloughing efficacy and healing outcomes in venous ulcers. Gethin G, Cowman S.  PMID: 18752540
Comparison of desloughing efficacy after four weeks and healing outcomes after 12 weeks in sloughy venous leg ulcers treated with Manuka honey (Woundcare 18+) vs. standard hydrogel therapy (IntraSite Gel). BACKGROUND: Expert opinion suggests that Manuka honey is effective as a desloughing agent but clinical evidence in the form of a randomised controlled trial is not available. There is a paucity of research which uses Manuka honey in venous ulcers. DESIGN: Prospective, multicentre, open label randomised controlled trial. METHOD: Randomisation was via remote telephone. One hundred and eight patients with venous leg ulcers having greater than or =50% wound area covered in slough, not taking antibiotics or immunosuppressant therapy were recruited from vascular centres, acute and community care hospitals and leg ulcer clinics. The efficacy of WoundCare 18+ to deslough the wounds after four weeks and its impact on healing after 12 weeks when compared with IntraSite Gel control was determined. Treatment was applied weekly for four weeks and follow-up was made at week 12. RESULTS: At week 4, mean % reduction in slough was 67% WoundCare 18+ vs. 52.9% IntraSite Gel (p = 0.054). Mean wound area covered in slough reduced to 29% and 43%, respectively (p = 0.065). Median reduction in wound size was 34% vs. 13% (p = 0.001). At 12 weeks, 44% vs. 33% healed (p = 0.037). Wounds having greater than 50% reduction in slough had greater probability of healing at week 12 (95% confidence interval 1.12, 9.7; risk ratio 3.3; p = 0.029). Infection developed in 6 of the WoundCare 18+ group vs. 12 in the IntraSite Gel group. CONCLUSION: The WoundCare 18+ group had increased incidence of healing, effective desloughing and a lower incidence of infection than the control. Manuka honey has therapeutic value and further research is required to examine its use in other wound aetiologies. RELEVANCE TO CLINICAL PRACTICE: This study confirms that Manuka honey may be considered by clinicians for use in sloughy venous ulcers. Additionally, effective desloughing significantly improves healing outcomes.
Biotechnol Res Int. 2011;2011:917505. Epub 2010 Dec 29. Antibacterial efficacy of raw and processed honey. Mohapatra DP, Thakur V, Brar SK.  PMID: 21350671
In vitro antibacterial activity of methanol, ethanol, and ethyl acetate extracts of raw and processed honey was tested against Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis, Bacillus cereus, Enterococcus faecalis, and Micrococcus luteus) and Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, and Salmonella typhi). Both types of honey showed antibacterial activity against tested organisms with the zone of inhibition (ZOI) ranging from 6.94 to 37.94 mm, while E. coli, S. typhi, and P. aeruginosa showed that sensibility towards all the extracts with ZOI ranges between 13.09 to 37.94 mm. The methanol extract showed more potent activity than other organic extracts. Gram-negative bacteria were found to be more susceptible as compared to Gram-positive bacteria except E. faecalis. The broth microdilution assay gave minimum inhibitory concentrations (MIC) value of 625 μg/mL, while the minimum bactericidal concentration (MBC) ranges between 625 μg/mL 2500 μg/mL. The study showed that honey has antibacterial activity (bacteriostatic and bactericidal effect), similar to antibiotics, against test organisms and provides alternative therapy against certain bacteria.
N Z Med J. 2009 May 22;122(1295):47-60. Honey in the treatment of burns: a systematic review and meta-analysis of its efficacy. Wijesinghe M, et al.  PMID: 19648986
Eight studies with 624 subjects were included in the meta-analysis. The quality of the studies was poor with each study having a Jadad score of 1. Six studies were undertaken by the same investigator. In most studies unprocessed honey covered by sterile gauze was compared with silver sulphadiazine-impregnated gauze. The fixed effects odds ratio for healing at 15 days was 6.1 (95% CI 3.7 to 9.9) in favour of honey having a superior effect. The random effects pooled odds ratio was 6.7 (95% CI 2.8 to 15.8) in favour of honey treatment. The secondary outcome variables all showed significantly greater efficacy for honey treatment. CONCLUSION: Available evidence indicates markedly greater efficacy of honey compared with alternative dressing treatments for superficial or partial thickness burns, although the limitations of the studies included in the meta-analysis restrict the clinical application of these findings. Further studies are urgently required to determine the role of honey in the management of superficial or partial thickness burns.
Ostomy Wound Manage. 2002 Nov;48(11):28-40. Re-introducing honey in the management of wounds and ulcers - theory and practice. Molan PC. PMID: 12426450  
Dressing wounds with honey, a standard practice in past times, went out of fashion when antibiotics came into use. Because antibiotic-resistant bacteria have become a widespread clinical problem, a renaissance in honey use has occurred. Laboratory studies and clinical trials have shown that honey is an effective broad-spectrum antibacterial agent that has no adverse effects on wound tissues. As well as having an antibacterial action, honey also provides rapid autolytic debridement, deodorizes wounds, and stimulates the growth of wound tissues to hasten healing and start the healing process in dormant wounds. Its anti-inflammatory activity rapidly reduces pain, edema, and exudate and minimizes hypertrophic scarring. It also provides a moist healing environment for wound tissues with no risk of maceration of surrounding skin and completely prevents adherence of dressings to the wound bed so no pain or tissue damage is associated with dressing changes. Using appropriate dressing practice overcomes potential messiness and handling problems.
PLoS One. 2011 Mar 4;6(3):e17709. Two major medicinal honeys have different mechanisms of bactericidal activity. Kwakman PH, et al.  PMID: 21394213
Honey is increasingly valued for its antibacterial activity, but knowledge regarding the mechanism of action is still incomplete. We assessed the bactericidal activity and mechanism of action of Revamil® source (RS) honey and manuka honey, the sources of two major medical-grade honeys. RS honey killed Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa within 2 hours, whereas manuka honey had such rapid activity only against B. subtilis. After 24 hours of incubation, both honeys killed all tested bacteria, including methicillin-resistant Staphylococcus aureus, but manuka honey retained activity up to higher dilutions than RShoney. Bee defensin-1 and H₂O₂ were the major factors involved in rapid bactericidal activity of RS honey. These factors were absent in manuka honey, but this honey contained 44-fold higher concentrations of methylglyoxal than RS honey. Methylglyoxal was a major bactericidal factor in manuka honey, but after neutralization of this compound manuka honey retained bactericidal activity due to several unknown factors. RS and manuka honey have highly distinct compositions of bactericidal factors, resulting in large differences in bactericidal activity.
Honey and Cesarean Healing

Eur J Med Res. 1999 Mar 26;4(3):126-30. Effects of topical honey on post-operative wound infections due to gram positive and gram negative bacteria following caesarean sections and hysterectomies. Al-Waili NS, Saloom KY.  PMID: 10085281
The possible therapeutic effect of topical crude undiluted honey in the treatment of severe acute postoperative wound infections was studied. Fifty patients having postoperative wound infections following caesarean sections or total abdominal hysterectomies with gram positive or gram negative bacterial infections were allocated in two groups. Twenty-six patients (group A) were treated with 12 hourly application of crude honey and 24 patients (group B) were treated with local antiseptics: spirit (70% Ethanol) and povidone-iodine. Both groups received systemic antibiotics according to culture and sensitivity. Results showed that eradication of bacterial infections was obtained after 6 +/- 1.9 days (mean +/- SD) in group A and after 14.8 +/- 4.2 days in group B (p less than 0.05). Period for antibiotics use was 6.88 +/- 1.7 days in-group A and 15.45 +/- 4. 37 in-group B (p less than 0.05). Complete wound healing was evident after 10. 73 +/- 2.5 days in group A and after 22.04 +/- 7.33 in group B (p less than 0. 05). Size of postoperative scar was 3.62 +/- 1.4 mm after using topical honey and was 8.62 +/- 3.8 mm after local antiseptics (p less than 0. 05). The mean hospital stay was 9.36 +/- 1.8 days in group A and 19. 91 +/- 7.35 days in group B (p less than 0.05). After using honey, 22/26 patients (84.4%) showed complete wound healing without wound disruption or need for re-suturing and only 4 patients showed mild dehiscence. In group B, 12/24 patients (50%) showed complete wound healing and 12 patients showed wound dehiscence, six of them needed re-suturing under general anesthesia. We concluded that topical application of crude undiluted honey could (1) faster eradication of bacterial infections, (2) reduce period of antibiotic use and hospital stay, (3) accelerate wound healing, (4) prevent wound dehiscence and need for re-suturing and (5) result in minimal scar formation.
Aust N Z J Obstet Gynaecol. 1992 Nov;32(4):381-4. Topical application of honey in treatment of abdominal wound disruption. Phuapradit W, Saropala N.  PMID: 1290445
The usefulness of honey application as an alternative method of managing abdominal wound disruption was assessed. Fifteen patients whose wound disrupted after Caesarean section were treated with honey application and wound approximation by micropore tape instead of the traditional method of wound dressing with subsequent resuturing. We achieved excellent results in all the cases with complete healing within 2 weeks. Honey application is inexpensive, effective and avoids the need to resuture which also requires general anaesthesia.